Valted Seq, Inc. announced that it has received $12.99 million in funding from DongKoo Bio&Pharma Co., Ltd., Loftyrock Investment Co., Ltd., OV Principal Investments, LLC and other investors
January 27, 2022
Share
On January 27, 2022, Valted Seq, Inc. closed the transaction. The company amended the terms of the transaction, and issued 1,000,000 shares for proceeds of $2,490,000 in its third tranche closing, bringing the total gross proceeds raised in the transaction to $12,990,000. The tranche included participation from DongKoo Bio&Pharma Co., Ltd. for 20,000 shares, and new investor Loftyrock Investment Co., Ltd. for 980,000 shares.
Post closing, DongKoo Bio&Pharma Co., Ltd. holds 5.31% stake in the company. The transaction has been approved by the board of directors of DongKoo Bio&Pharma Co., Ltd.
Dongkoo Bio&Pharma Co.,Ltd. is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The major products include antihistamines, topical steroids, therapeutic agents for prostatitis, treatments for benign prostatic hyperplasia, atherosclerotic agents, and antibiotics, among others. The Company is involved in contract manufacturing organization business. It manufactures and sells therapeutic for osteoporosis, antiviral agents, erectile dysfunction treatments, hepatic disease agents; painkillers; gum treatments. In addition, the Company is engaged in the manufacturing and sale of medical devices and cosmetics. The Company distributes its products within the domestic market and to overseas markets, including America and Europe.
Valted Seq, Inc. announced that it has received $12.99 million in funding from DongKoo Bio&Pharma Co., Ltd., Loftyrock Investment Co., Ltd., OV Principal Investments, LLC and other investors
DONGKOO BIO & PHARMA CO., LTD. 
